Prestige Plans ‘Strong Price Competitiveness’ For Its Adalimumab Biosimilar
Discloses Phase I Details And Phase III Plans Ahead Of Filings In EU And US
As Prestige BioPharma announced plans for Phase I and Phase III trials of its PBP1502 proposed adalimumab biosimilar, as well as expected filing dates in the EU and US, the company outlined how it believes its proprietary technology will allow its Humira rival to compete aggressively on price.
